Company(ies): Medarex, Bristol-Myers Squibb
Principal Therapy Area: Cancer
£195 / $340 / €245
Ipilimumab (formerly MDX-010) is a fully human monoclonal antibody (IgG1 isotype) being investigated as an anticancer treatment. It is in a novel class of agents intended to potentiate elements of the immunologic response. Ipilimumab works against human CTLA-4, a molecule on T-cells that is believed to be responsible for suppressing the immune response. Medarex and Bristol-Myers Squibb are investigating the potential of ipilimumab to enable the immune systems of cancer patients to help suppress tumour growth.
Development risk data looks promising in prostate cancer, lung cancer and melanoma.
Use this Cancer Drug Futures report to analyse key drivers and dampeners of success
An extensive review of the factors which can affect this product's clinical and commercial performance. Each drug report provides and covers…
What you get
A copy of the Cancer Drug Futures report(s) in print or pdf as you wish
Are you interested in more than one product, indication or therapy area?
Why not build a specific drug futures library and save money!
We appreciate that some customers will need to review many products. That is why, if you buy more than 5 Cancer Drug Futures reports of your choice, we can arrange
Customers focusing on specific disease areas can benefit from buying our cost-effective Cancer Drug Futures collections. Collections are available for the following cancer sectors:
For further information on the products covered, discounts, distribution or a demonstration, please click on the link for firstname.lastname@example.org